方盛製藥(603998.SH):受讓藥品上市許可
格隆匯3月26日丨方盛製藥(603998.SH)公佈,2025年3月25日,公司與康溢醫藥、自然人李明志先生簽訂了《藥品品種轉讓協議》,決定受讓“喉咽清膠囊”“浙貝止咳露(黃盒)”等20個在香港衛生署註冊的藥品品種所有權;並於同日與港捷公司、自然人趙國灝先生及向紅梅女士簽訂《投資合作協議》,擬在香港成立合資子公司,註冊資本2,000萬港元,公司以自有資金出資700萬港元,持股35%,爲公司控股子公司(根據《投資合作協議》相關條款約定,合資子公司董事會由三名董事組成,其中公司委派兩名代表擔任董事,對該公司具有控制權,納入公司合併報表範圍內);該合資子公司成立後,其將按照《投資合作協議》《藥品品種轉讓協議》的相關約定,與康溢醫藥就上述20個藥品品種轉讓重新簽訂《藥品品種轉讓協議》並履行相關義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.